Fastest Growing Stocks
ACAD is part of our fastest growing stocks screen, indicating it has high EPS and sales growth.
ACADIA PHARMACEUTICALS INC (ACAD) Stock Price & Overview
NASDAQ:ACAD • US0042251084
Current stock price
22.2 USD
-0.12 (-0.54%)
At close:
22.2 USD
0 (0%)
After Hours:
The current stock price of ACAD is 22.2 USD. Today ACAD is down by -0.54%. In the past month the price decreased by -0.89%. In the past year, price increased by 44.34%.
ACAD Key Statistics
52-Week Range13.4 - 28.35
Current ACAD stock price positioned within its 52-week range.
1-Month Range19.89 - 22.915
Current ACAD stock price positioned within its 1-month range.
- Market Cap
- 3.785B
- P/E
- 9.69
- Fwd P/E
- 43.89
- EPS (TTM)
- 2.29
- Dividend Yield
- N/A
ACAD Stock Performance
Today
-0.54%
1 Week
+3.40%
1 Month
-0.89%
3 Months
-15.56%
Longer-term
6 Months +1.83%
1 Year +44.34%
2 Years +32.85%
3 Years +4.08%
5 Years +7.98%
10 Years -31.27%
ACAD Stock Chart
ACAD Stock Screens
ACAD currently appears in the following ChartMill screener lists.
ACAD Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to ACAD. When comparing the yearly performance of all stocks, ACAD turns out to be only a medium performer in the overall market: it outperformed 66.52% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
ACAD Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to ACAD. ACAD is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
ACAD Earnings
On February 25, 2026 ACAD reported an EPS of 1.6 and a revenue of 283.99M. The company beat EPS expectations (1044.15% surprise) and missed revenue expectations (-4.84% surprise).
Next Earnings DateMay 5, 2026
Last Earnings DateFeb 25, 2026
PeriodQ4 / 2025
EPS Reported$1.60
Revenue Reported283.989M
EPS Surprise 1,044.15%
Revenue Surprise -4.84%
ACAD Forecast & Estimates
27 analysts have analysed ACAD and the average price target is 32.37 USD. This implies a price increase of 45.82% is expected in the next year compared to the current price of 22.2.
For the next year, analysts expect an EPS growth of -77.91% and a revenue growth 15.61% for ACAD
Analysts
Analysts78.52
Price Target32.37 (45.81%)
EPS Next Y-77.91%
Revenue Next Year15.61%
ACAD Groups
Sector & Classification
ACAD Financial Highlights
Over the last trailing twelve months ACAD reported a non-GAAP Earnings per Share(EPS) of 2.29. The EPS increased by 377.08% compared to the year before.
Income Statements
Revenue(TTM)1.07B
Net Income(TTM)391.00M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 36.49% | ||
| ROA | 25% | ||
| ROE | 31.86% | ||
| Debt/Equity | 0 |
Chartmill High Growth Momentum
EPS Q2Q%8100%
Sales Q2Q%9.39%
EPS 1Y (TTM)377.08%
Revenue 1Y (TTM)113.98%
ACAD Ownership
Ownership
Inst Owners98.63%
Shares170.49M
Float168.22M
Ins Owners0.26%
Short Float %5.13%
Short Ratio4.92
ACAD Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.07 | 369.265B | ||
| AMGN | AMGEN INC | 15.24 | 187.564B | ||
| GILD | GILEAD SCIENCES INC | 15.81 | 173.439B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.63 | 111.445B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.3 | 80.543B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.73 | 42.286B | ||
| INSM | INSMED INC | N/A | 35.012B | ||
| NTRA | NATERA INC | N/A | 29.477B | ||
| BIIB | BIOGEN INC | 11.03 | 26.026B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.91 | 24.756B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.643B | ||
| MRNA | MODERNA INC | N/A | 19.431B | ||
| INCY | INCYTE CORP | 12.53 | 19.091B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ACAD
Company Profile
ACADIA Pharmaceuticals, Inc. engages in the development and commercialization of medicines for central nervous system disorders. The company is headquartered in San Diego, California and currently employs 796 full-time employees. The company went IPO on 2004-05-27. The company develops and commercializes medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. The company has a portfolio of product candidates and research programs that are designed to address significant unmet medical needs in CNS disorders and rare diseases. Its pipeline includes NUPLAZID (pimavanserin), DAYBUE (trofinetide), ACP-101, ACP-204, and ACP-711. NUPLAZID is a selective serotonin inverse agonist/antagonist preferentially targeting the 5-HT2A receptor. NUPLAZID is developed for the treatment for Parkinson's Disease Psychosis. Trofinetide is a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 designed to treat the core symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function. Its early-stage research programs and product candidates include ACP-211, ACP-2591, ACP-271, and Antisense Oligonucleotide (ASO) Programs.
Company Info
IPO: 2004-05-27
ACADIA PHARMACEUTICALS INC
12830 El Camino Real, Suite 400
San Diego CALIFORNIA 92130 US
CEO: Stephen R. Davis
Employees: 796
Phone: 18585582871
ACADIA PHARMACEUTICALS INC / ACAD FAQ
What does ACAD do?
ACADIA Pharmaceuticals, Inc. engages in the development and commercialization of medicines for central nervous system disorders. The company is headquartered in San Diego, California and currently employs 796 full-time employees. The company went IPO on 2004-05-27. The company develops and commercializes medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. The company has a portfolio of product candidates and research programs that are designed to address significant unmet medical needs in CNS disorders and rare diseases. Its pipeline includes NUPLAZID (pimavanserin), DAYBUE (trofinetide), ACP-101, ACP-204, and ACP-711. NUPLAZID is a selective serotonin inverse agonist/antagonist preferentially targeting the 5-HT2A receptor. NUPLAZID is developed for the treatment for Parkinson's Disease Psychosis. Trofinetide is a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 designed to treat the core symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function. Its early-stage research programs and product candidates include ACP-211, ACP-2591, ACP-271, and Antisense Oligonucleotide (ASO) Programs.
What is the stock price of ACADIA PHARMACEUTICALS INC today?
The current stock price of ACAD is 22.2 USD. The price decreased by -0.54% in the last trading session.
Does ACAD stock pay dividends?
ACAD does not pay a dividend.
How is the ChartMill rating for ACADIA PHARMACEUTICALS INC?
ACAD has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
Should I buy ACAD stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on ACAD.
Can you provide the growth outlook for ACADIA PHARMACEUTICALS INC?
The Revenue of ACADIA PHARMACEUTICALS INC (ACAD) is expected to grow by 15.61% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the next earnings date for ACAD stock?
ACADIA PHARMACEUTICALS INC (ACAD) will report earnings on 2026-05-05.